1. Home
  2. TSE vs PHGE Comparison

TSE vs PHGE Comparison

Compare TSE & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinseo PLC

TSE

Trinseo PLC

HOLD

Current Price

$0.23

Market Cap

8.3M

Sector

Industrials

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$6.72

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSE
PHGE
Founded
2010
2015
Country
United States
United States
Employees
N/A
57
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
9.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
TSE
PHGE
Price
$0.23
$6.72
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$1.00
$26.00
AVG Volume (30 Days)
749.8K
82.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
50.40
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.25
52 Week High
$4.66
$8.50

Technical Indicators

Market Signals
Indicator
TSE
PHGE
Relative Strength Index (RSI) 27.26 62.96
Support Level N/A $0.41
Resistance Level $0.51 $8.50
Average True Range (ATR) 0.06 0.78
MACD -0.01 0.08
Stochastic Oscillator 0.33 84.59

Price Performance

Historical Comparison
TSE
PHGE

About TSE Trinseo PLC

Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: